GSK, Pfizer RSV vaccine sales fall in US as millions fewer people line up
U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and ...
Analysis-GSK, Pfizer RSV Vaccine Sales Fall in US as Millions Fewer People Line Up
(Reuters) - U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age ...
Pfizer wins bid to invalidate GSK's patents over RSV vaccine
Pfizer on Monday won a bid in a London court to invalidate two of GSK's patents relating to a respiratory syncytial virus ...
GSK Presents Positive Data for AREXVY, Its Respiratory Syncytial Virus (RSV) Vaccine, Indicating Protection Over Three RSV Seasons
GSK presents positive data for AREXVY, its respiratory syncytial virus (RSV) vaccine, indicating protection over three RSV ...
Making an RSV Vaccine Was Hard. Getting People to Take It Is Even Harder
RSV hospitalizes thousands of people in the US every year. Three new vaccines could help stem the spread, but there are ...
GlobalData on MSN17h
GSK reports positive findings from Phase III RSV vaccine trial
The vaccine demonstrated efficacy across different respiratory syncytial virus (RSV) subtypes in older adults between the ...
GSK Arexvy protects from RSV over three full seasons
GSK (GSK) announces that its Arexvy vaccine shows promise in protecting adults aged 60+ against RSV over three seasons in a ...
FiercePharma1d
GSK touts 3-year data on RSV shot Arexvy after CDC's narrower usage recommendation
While recent CDC guidance threatens to shrink the market for a new class of immunizations, GSK continues to build the case ...
BioPharma Dive1d
GSK says RSV vaccine protects against disease over three seasons
Cumulatively, data showed the shot to be 63% effective across the three-year period. However, efficacy appeared to wane and GSK said it expects revaccination will eventually be needed.
McKnight's Long-Term Care News1d
RSV vaccine still 43.3 percent effective 3 years after people take it, trial shows
GSK announced on Tuesday that a single dose of its Arexvy vaccine against respiratory syncytial virus (RSV) was 43.3% ...
GSK Announces Positive Data From AReSVi-006 Phase III Trial For RSV Vaccine Arexvy
GSK plc (GSK, GSK.L) announced Tuesday new data from the AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial evaluating ...
Pharmabiz22h
GSK presents positive data from AReSVi-006 phase III trial of respiratory syncytial virus vaccine, Arexvy at CHEST 2024 annual meeting
GSK presents positive data from AReSVi-006 phase III trial of respiratory syncytial virus vaccine, Arexvy at CHEST 2024 annual meeting: London, UK Wednesday, October 9, 2024, 14:0 ...